top of page

NICE says ‘no’ to alirocumab in draft guidance

The National institute for Health and Care Excellence (NICE) has published draft guidance not recommending Praluent (alirocumab, Sanofi/Regeneron) as an option for people with primary hypercholesterolaemia (heterozygous-familial and non-familial) and mixed dyslipidaemia.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page